Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

NCT00280865 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00280865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00280865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
June 30, 2003
Enrollment
500
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes